在外部环境动荡的背景下,CXO一哥药明康德(603259.SH/2359.HK)却交出了一份“摆脱地心引力”的超预期业绩:2025年一季度营收达96.5亿元,同比增长21.0%;经调整non-IFRS归母净利润26.8亿元,同比增长40.0%;持续经营业务在手订单523.3亿元,同比增长47.1%。尽管医药行业面临的外部环境并未显著改善,但从药明康德这份一季报来看,外部因素的影响更多只停留在心理...
Source Link在外部环境动荡的背景下,CXO一哥药明康德(603259.SH/2359.HK)却交出了一份“摆脱地心引力”的超预期业绩:2025年一季度营收达96.5亿元,同比增长21.0%;经调整non-IFRS归母净利润26.8亿元,同比增长40.0%;持续经营业务在手订单523.3亿元,同比增长47.1%。尽管医药行业面临的外部环境并未显著改善,但从药明康德这份一季报来看,外部因素的影响更多只停留在心理...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.